TesamorelinvsTesofensine

Tesamorelin is a synthetic GHRH analogue consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This lipophilic modification enhances receptor binding affinity and provides modest resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, improving its pharmacokinetic profile compared to native GHRH.

Like other GHRH analogues, tesamorelin activates the GHRH receptor on pituitary somatotrophs via the Gs/cAMP/PKA pathway, stimulating endogenous GH synthesis and pulsatile secretion. The resulting increase in circulating GH and IGF-1 produces its primary therapeutic effect: targeted reduction of visceral adipose tissue (VAT). GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation.

The specificity of tesamorelin's effect on visceral rather than subcutaneous fat has been well-documented in clinical trials. Visceral adipose tissue is metabolically distinct — it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone. Clinical trials also showed improvements in hepatic steatosis (fatty liver) markers, triglyceride levels, and trunk fat distribution. It remains the only GHRH analogue with active FDA approval, specifically for HIV-associated lipodystrophy, where visceral fat accumulation is a common and distressing side effect of antiretroviral therapy.

Tesofensine is a novel triple monoamine reuptake inhibitor (TRI) that simultaneously blocks the presynaptic reuptake transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT). Originally developed by NeuroSearch as NS2330 for neurodegenerative diseases, it was repurposed for obesity after clinical trials for Alzheimer's and Parkinson's disease unexpectedly revealed significant weight loss in treated patients.

The weight loss mechanism involves all three monoamine systems working in concert. Serotonin (5-HT) reuptake inhibition increases serotonergic tone in the hypothalamic appetite centers, particularly the paraventricular nucleus and ventromedial hypothalamus. Elevated synaptic serotonin activates 5-HT2C receptors on POMC neurons, promoting the release of alpha-MSH, which activates MC4R and produces satiety. This is the same pathway targeted by lorcaserin (Belviq), but tesofensine adds two additional mechanisms. Norepinephrine reuptake inhibition activates alpha-1 and beta-adrenergic receptors in the lateral hypothalamus, reducing appetite and increasing sympathetic nervous system activity, which raises basal metabolic rate and thermogenesis.

The dopamine reuptake inhibition component may be the most important differentiator. By increasing dopamine availability in the mesolimbic reward pathway (nucleus accumbens, ventral tegmental area), tesofensine may reduce the drive for food reward-seeking behavior — the compulsive eating of palatable, high-calorie foods that is mediated by dopamine signaling in the same circuits involved in addiction. This addresses a component of obesity that pure appetite suppressants miss: the hedonic (pleasure-driven) eating that overrides homeostatic satiety signals. Phase II clinical trials demonstrated remarkable efficacy — the 0.5 mg dose produced approximately 12.8 kg weight loss over 6 months, roughly double what GLP-1 receptor agonists typically achieve — though cardiovascular monitoring is necessary due to increases in heart rate associated with the noradrenergic and dopaminergic effects.